[go: up one dir, main page]

WO2015179823A8 - Lung localized inhibitors of alpha(v)beta 6 - Google Patents

Lung localized inhibitors of alpha(v)beta 6 Download PDF

Info

Publication number
WO2015179823A8
WO2015179823A8 PCT/US2015/032275 US2015032275W WO2015179823A8 WO 2015179823 A8 WO2015179823 A8 WO 2015179823A8 US 2015032275 W US2015032275 W US 2015032275W WO 2015179823 A8 WO2015179823 A8 WO 2015179823A8
Authority
WO
WIPO (PCT)
Prior art keywords
lung
beta
alpha
localized
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/032275
Other languages
French (fr)
Other versions
WO2015179823A3 (en
WO2015179823A2 (en
Inventor
Arnab K. Chatterjee
Luke LAIRSON
Natasha LUCKI
Joshua David SEITZ
Peter G. Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute for Biomedical Research
Original Assignee
California Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute for Biomedical Research filed Critical California Institute for Biomedical Research
Publication of WO2015179823A2 publication Critical patent/WO2015179823A2/en
Publication of WO2015179823A3 publication Critical patent/WO2015179823A3/en
Publication of WO2015179823A8 publication Critical patent/WO2015179823A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are compounds, compositions, and methods of their use treatment of a lung disease.
PCT/US2015/032275 2014-05-23 2015-05-22 Lung localized inhibitors of alpha(v)beta 6 Ceased WO2015179823A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462002621P 2014-05-23 2014-05-23
US62/002,621 2014-05-23

Publications (3)

Publication Number Publication Date
WO2015179823A2 WO2015179823A2 (en) 2015-11-26
WO2015179823A3 WO2015179823A3 (en) 2016-05-19
WO2015179823A8 true WO2015179823A8 (en) 2016-08-11

Family

ID=54554981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032275 Ceased WO2015179823A2 (en) 2014-05-23 2015-05-22 Lung localized inhibitors of alpha(v)beta 6

Country Status (1)

Country Link
WO (1) WO2015179823A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201835078A (en) 2017-02-28 2018-10-01 美商萊築理公司 Inhibitors of [alpha]v[beta]6 integrin
MA52117A (en) 2017-02-28 2022-04-06 Morphic Therapeutic Inc INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
US11597701B2 (en) * 2017-11-01 2023-03-07 Arrowhead Pharmaceuticals, Inc. Integrin ligands and uses thereof
MX2021002181A (en) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibiting î±v î²6 integrin.
US20230096766A1 (en) 2018-12-12 2023-03-30 Chugai Seiyaku Kabushiki Kaisha Amino acid having functional group capable of intermolecular hydrogen bonding, peptide compound containing same and method for production thereof
WO2022216920A1 (en) 2021-04-08 2022-10-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
CN120676964A (en) 2022-11-17 2025-09-19 H-G·勒珍 Small molecule-drug conjugates cleavable in tumor microenvironments
CN120574222A (en) * 2024-03-01 2025-09-02 长春金赛药业有限责任公司 Integrin ligands and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036003A2 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
DE10112771A1 (en) * 2001-03-16 2002-09-26 Merck Patent Gmbh New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
WO2008030158A1 (en) * 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
GB0922014D0 (en) * 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders

Also Published As

Publication number Publication date
WO2015179823A3 (en) 2016-05-19
WO2015179823A2 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
EP3448874A4 (en) Compositions for the treatment of disease
EP3448987A4 (en) Compositions for the treatment of disease
WO2015117081A3 (en) Methods and compositions for treatment of a beta thalessemia
IL255509B (en) Compounds as ccr2 modulators, pharmaceutical compositions comprising same and their use for the treatment of diseases
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
SI3672954T1 (en) Compounds, salts thereof and their use for the treatment of diseases
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX369623B (en) Fused bicyclic compounds for the treatment of disease.
EP3139935A4 (en) Therapeutic placental compositions, methods of making and methods of use
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
EP3285874A4 (en) Compositions and methods for treating mycobacteria infections and lung disease
HK1259441A1 (en) Formulations/compositions comprising a btk inhibitor
IL252897A0 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
MX382092B (en) Heterocyclic compounds for the treatment of disease
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
HK1249756A1 (en) Fused bicyclic compounds for the treatment of disease
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
EP3820477A4 (en) Compounds, compositions, and methods for the treatment of disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15795566

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15795566

Country of ref document: EP

Kind code of ref document: A2